{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-000151","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.190441+00:00","generated_at":"2026-05-28T02:53:59.424993+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"MaxCyte reports preliminary FY2024 core revenue $32.2M-$32.4M, up 8-9% YoY","bullets":["Q4 2024 core revenue expected $8.3M–$8.5M vs $7.2M in Q4 2023.","Full-year core revenue $32.2M–$32.4M, up 8–9% from $29.8M in FY2023.","Cash and investments ~$190M at Dec 31, 2024, above updated guidance of $185M.","Added six SPL customers in 2024; supported launch of first FDA-approved non-viral gene-edited cell therapy.","Audited FY2024 results expected in March 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-000151","json":"https://secwatch.observer/filing/0001558370-25-000151.json","markdown":"https://secwatch.observer/filing/0001558370-25-000151.md","text":"https://secwatch.observer/filing/0001558370-25-000151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837025000151/0001558370-25-000151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837025000151/mxct-20250113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:53:59.424993+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}